Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-marketing Clinical Study of Ipragliflozin; Multicenter, Open-label Study to Assess the Efficacy of Ipragliflozin Add-on in Reducing Insulin Dose in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy

NCT02847091 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT02847091
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02847091 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-marketing Clinical Study of Ipragliflozin; Multicenter, Open-label Study to Assess the Efficacy of Ipragliflozin Add-on in Reducing Insulin Dose in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy
Lead sponsor
Astellas Pharma Inc
Phase
Phase 4
Overall status
Completed
Start date
July 29, 2016
Completion date
November 9, 2017
Enrollment
103 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus